Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Home
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Next Post
Previous Post
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
October 12, 2021
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Aadi Bioscience to Participate in Upcoming Investor Conferences
Mohammad Hirmand, MD
Phase II Trial of
nab
-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update
ABI-009 (
nab
-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of
nab
-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
and
TSC2
Response to Treatment With
nab
-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Characterizing the genomic landscape of malignant perivascular epithelioid cell family of tumors (PEComa-FT) in a real-world population using the Foundation Medicine genomic database
Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.